Shire pledges $260M-plus in deal for liver-focused Lumena

Lumena won't be going through with that $75 million IPO after all. Shire is scooping up the company and its two development programs for rare liver diseases for $260 million in cash along with an undisclosed slate of milestones. The deal comes as analysts buzz about whether Shire ($SHPG) itself may be targeted for an acquisition by either AstraZeneca ($AZN) or Allergan ($AGN), which are both trying to wrestle out of the grip of an unwelcome buyout offer. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.